Emergent BioSolutions | EBS - Equity Capital And Reserves


Emergent BioSolutions reported $649.3M in Equity Capital and Reserves for its fiscal quarter ending in December of 2023.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
ALKERMES USD 1.75B 67.76M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Exelixis USD 1.94B 225.57M Mar/2026
Glaxosmithkline GBP 22.06B 360M Dec/2025
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
Lonza CHF 9.13B 513M Dec/2025
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Sanofi EUR 72.81B 1.1B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025
Xoma USD 87.94M 15.5M Sep/2025